What Does InflaRx Do?

Total employees52
HeadquartersJena
Founded2007

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of C5a and C5aR. C5a is a powerful inflammatory mediator involved in a wide variety of autoimmune and other inflammatory diseases. The company's lead product candidate, vilobelimab, is a novel intravenously administered first-in-class monoclonal anti-C5a antibody, which has demonstrated activity in various disease settings, including emergency use authorization in the US for critically ill COVID-19 patients. InflaRx is also developing other C5a/C5aR inhibitors for various indications.

Where Is InflaRx's Headquarters?

HQ Function

Serves as the global operational and research & development hub, overseeing clinical trial management, drug discovery, corporate strategy, and administrative functions.

Notable Features:

Located in Jena, a city renowned as a German center for optics, life sciences, and research (BioRegio Jena), providing access to a skilled talent pool and collaborative opportunities with universities and research institutions. The facility likely includes modern office spaces and potentially laboratory facilities.

Work Culture:

A science-driven, innovative, and collaborative environment focused on advancing novel therapeutics. The culture likely emphasizes meticulous research, teamwork across disciplines (R&D, clinical, regulatory), and a shared mission to address severe inflammatory conditions.

HQ Significance:

The Jena headquarters is pivotal for InflaRx's core R&D activities, intellectual property development, and strategic decision-making. Its location in Germany leverages the country's strong biopharmaceutical infrastructure and scientific talent.

Values Reflected in HQ: The headquarters' location in a strong research hub reflects InflaRx's commitment to scientific excellence, innovation, and leveraging cutting-edge research to develop its therapeutic pipeline.

Location:

InflaRx operates with a global strategic focus, primarily centered in Europe and North America. Its R&D and corporate headquarters are in Jena, Germany, while its U.S. subsidiary in Ann Arbor, Michigan, supports clinical development, regulatory affairs, and business operations in the U.S. The company conducts multinational clinical trials for its product candidates, engaging with regulatory agencies worldwide.

Street Address:

Winzerlaer Str. 2

City:

Jena

State/Province:

Thuringia

Country:

Germany

Where Else Does InflaRx Operate Around the World?

Ann Arbor, Michigan, USA

Address: 2000 Green Road, Suite 200, Ann Arbor, MI 48105, USA

To manage and advance clinical trials within the United States, facilitate regulatory interactions, and support potential future commercialization efforts in the key North American market.

Buying Intent Signals for InflaRx

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading InflaRx? Meet the Executive Team

As of April 2025, InflaRx' leadership includes:

Prof. Dr. Niels C. Riedemann - Chief Executive Officer & Founder
Jordan Zwick - Interim Chief Financial Officer and Head of Business Development
Prof. Dr. Renfeng Guo - Chief Scientific Officer & Founder
Dr. Arnd Scheel - Chief Operating Officer and General Counsel
Dr. Camilla Chong - Chief Medical Officer

Who's Investing in InflaRx?

InflaRx has been backed by several prominent investors over the years, including:

Staidson (Hong Kong) Investment Company Limited
BVF Partners L.P.
RA Capital Management, L.P.
Cormorant Asset Management, LP
Avidity Partners Management LP
Various other institutional investors and funds

What Leadership Changes Has InflaRx Seen Recently?

Hire2
Exits1

Over the past 12 months (mid-2023 to mid-2024), InflaRx experienced key changes in its executive team, including the departure of its Chief Financial Officer, the appointment of an Interim CFO, and the promotion of its Chief Business Officer to Chief Operating Officer.

Departures

Thomas Taapken, Thomas Taapken stepped down as Chief Financial Officer, effective December 31, 2023.

New Appointments:

Jordan Zwick, Jordan Zwick was appointed Interim Chief Financial Officer, also continuing as Head of Business Development.
Dr. Arnd Scheel, Dr. Arnd Scheel was promoted to the expanded role of Chief Operating Officer, while retaining his responsibilities as General Counsel.

What Technology (Tech Stack) Is Used byInflaRx?

Discover the tools InflaRx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

InflaRx Email Formats and Examples

InflaRx likely utilizes standard corporate email formats. Common patterns for companies like InflaRx include [first_initial].[last]@[companydomain].com or [first_name].[last_name]@[companydomain].com. The primary domain is inflarx.com.

[first_initial].[last]@inflarx.com

Format

n.riedemann@inflarx.com

Example

85%

Success rate

What's the Latest News About InflaRx?

InflaRx N.V. / GlobeNewswireMarch 27, 2024

InflaRx Reports Full Year 2023 Financial Results and Provides Business Update

InflaRx announced its financial results for the fiscal year ended December 31, 2023, and provided a comprehensive business update. The report highlighted progress in its clinical programs, including vilobelimab, and outlined strategic priorities for future development and potential commercialization....more

InflaRx N.V. / GlobeNewswireMarch 18, 2024

InflaRx Announces Positive Topline Data from Phase II Study of Vilobelimab in ANCA-Associated Vasculitis (AAV)

InflaRx reported positive topline results from its Phase II IXPLORE study, which evaluated vilobelimab in patients with ANCA-associated vasculitis. The study successfully met its primary endpoint, demonstrating a statistically significant improvement in disease activity for patients treated with vilobelimab plus standard of care compared to placebo plus standard of care....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including InflaRx, are just a search away.